Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Melphalan for Intraocular Retinoblastoma

NCT05504291 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT05504291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05504291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Melphalan for Intraocular Retinoblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2022
Completion date
March 31, 2028
Enrollment
26 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bilateral retinoblastoma, childhood intraocular retinoblastoma, group d retinoblastoma, stage i retinoblastoma, unilateral retinoblastoma